Soleus Capital Management, L.P. Belite Bio, Inc Call Options Transaction History
Soleus Capital Management, L.P.
- $1.64 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLTE
# of Institutions
27Shares Held
793KCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA875KShares$102 Million1.11% of portfolio
-
Vestal Point Capital, LP New York, NY313KShares$36.5 Million1.04% of portfolio
-
Rtw Investments, LP New York, NY313KShares$36.5 Million0.31% of portfolio
-
Eventide Asset Management, LLC Boston, MA195KShares$22.8 Million0.27% of portfolio
-
Marshall Wace, LLP London, X0188KShares$21.9 Million0.02% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.9B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...